-
Adding abiraterone to ADT plus docetaxel significantly improves PFS in patients who present de novo mCSPC without meaningful added short-term toxicity according to phase 3 PEACE-1 trial.
-
Phase 3 RELATIVITY-047 trial results validate the efficacy of dual checkpoint blockade shown with the LAG-3 inhibitor relatlimab and nivolumab in advanced melanoma patients.
-
Analysis of phase 3 trials with atezolizumab in stage IV NSCLC patients shows longer overall survival for those experiencing immune-related AEs.
-
Analysis of 1,000 patients in the MINDACT trial identifies patients with ultra-low risk for distant recurrence. These patients could be candidates for further de-escalation of treatment.
-
Patritumab deruxtecan demonstrates anti-tumour activity across various EGFR TKI resistance mechanisms in heavily pretreated, metastatic/locally advanced, EGFR-mutated NSCLC.
-
After initial results over 5 years ago, long-term follow-up data from 3 clinical trials – CheckMate 067, COLUMBUS, and ABC – show a durable and sustained clinical benefit for patients with melanoma.
-
First-line treatment of patients with MSI-H/dMMR metastatic colorectal cancer (mCRC) with pembrolizumab improves overall survival, but the prespecified threshold for significance was not reached.
-
The method is called "Augmented Psychotherapy" and shows how depression can be treated when psychotherapy and psychopharmacology are combined.
-
The UK notified the WHO of a PCR-confirmed monkeypox case on a patient that lived and worked in Delta State, Nigeria. A second case was confirmed on 31 May 2021.
-
Polypharmacy in RA is associated with increased disease activity, an increased risk of serious adverse events (AEs), and a decreased treatment response.
-
The phase 3 OUTBACK trial results do not support the use of adjuvant chemotherapy after chemoradiation in women with locally advanced cervical cancer.
-
Patients with SLE have an increased risk of developing severe infections compared with non-SLE cases. Moreover, 21% of the mortality in SLE is related to these infections.
-
A significantly improved invasive disease-free survival in patients with high risk, HER2-negative, germline BRCA1/2-mutated primary breast cancer is found after 1 year of adjuvant treatment with olaparib.
-
Adhering to the healthy Dietary Approaches to Stop Hypertension (DASH) diet decreased the risk of gout in women. This effect was more pronounced in genetically predisposed individuals.
-
Adding the BCL2 inhibitor venetoclax to endocrine therapy does not improve clinical benefit for ER-positive, HER2-negative, locally advanced/metastatic breast cancer patients.
-
Risankizumab treatment leads to better-than-placebo signs and symptoms in active PsA patients with inadequate response or intolerance to 1 or 2 biologic therapies or at least one DMARD therapy.
-
First phase-3 CheckMate 648 study results demonstrate higher first-line treatment OS with nivolumab + ipilimumab, or nivolumab + chemotherapy, versus chemotherapy only.
-
esanum provides an overview of how you as a medical professional can help and proactively support humanitarian and medical aid projects.
-
A study investigated the safety profiles of COVID-19 vaccines in patients with rheumatic and musculoskeletal diseases (RMD) finding that these vaccines are safe and well tolerated in these patients.
-
A CheckMate 9LA trial update shows sustained benefit of first-line treatment with nivolumab plus ipilimumab plus 2 cycles of chemotherapy versus chemotherapy alone in patients with advanced NSCLC.
